Rheumatoid arthritis pathophysiology: Update on emerging cytokine and cytokine-associated cell targets

Rheumatology (United Kingdom)

Volumn 53, Issue 9, 2014, Pages 1560-1569

  Furst, Daniel E ^a   Emery, Paul ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Autoimmune disease; Biologic; IL 12; IL 17; IL 17A; IL 23; Inflammation; Rheumatoid arthritis; Synovitis; Th17 cell

Indexed keywords

BARICITINIB; BRODALUMAB; DECERNOTINIB; GLPG 0634; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR BETA1; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 17F; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; IXEKIZUMAB; METHOTREXATE; RITUXIMAB; SECUKINUMAB; TOCILIZUMAB; TOFACITINIB; UNCLASSIFIED DRUG; USTEKINUMAB;

AMINO ACID SUBSTITUTION; AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL INTERACTION; DAS28; DOUBLE BLIND PROCEDURE; GENETIC VARIABILITY; GENOTYPE; HUMAN; INFLAMMATION; MOLECULAR PATHOLOGY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE SUBPOPULATION; TARGET CELL; TH17 CELL; VASCULARIZATION;

EID: 84906827120     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket414     Document Type: Review

References (81)

1. Horton S, Walsh C, Emery P. Established rheumatoid arthritis: rationale for best practice: physicians' perspective of how to realize tight control in clinical practice. Best Pract Res Clin Rheumatol 2011;25:509-21.
2. Mewar D, Wilson AG. Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors. Br J Pharmacol 2011;162:785-91.
3. Burmester GR, Blanco R, Charles-Schoeman C et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013;381: 451-60.
4. Mosmann TR, Cherwinski H, Bond MW et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-57.
5. McInnes I, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19.
6. Harrington LE, Hatton RD, Mangan PR et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123-32.
7. Park H, Li Z, Yang XO et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6:1133-41.
8. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009;361:888-98.
9. Zhu S, Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci (Lond) 2012;122:487-511.
10. Paunovic V, Carroll HP, Vandenbroeck K et al. Signalling, inflammation and arthritis: crossed signals: the role of interleukin (IL)-12, -17, -23 and -27 in autoimmunity. Rheumatology 2008;47:771-6.
11. Kim W, Min S, Cho M et al. The role of IL-12 in inflammatory activity of patients with rheumatoid arthritis (RA). Clin Exp Immunol 2000;119:175-81.
12. Morita Y, Yamamura M, Nishida K et al. Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis. Arthritis Rheum 1998;41:306-14.
13. Brennan F, McInnes I. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008;118: 3537-45.
14. Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol 2012;13:722-8.
15. Pope RM, Shahrara S. Possible roles of IL-12-family cytokines in rheumatoid arthritis. Nat Rev Rheumatol 2013;9:252-6.
16. Astry B, Harberts E, Moudgil K. A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis. J Interferon Cytokine Res 2011;31:927-40.
17. Rong C, Hu W, Wu F et al. Interleukin-23 as a potential target for rheumatoid arthritis. Mol Cell Biochem 2012; 361:243-8.
18. Mai J, Wang H, Yang X-F. Th 17 cells interplay with Foxp3+ Tregs in regulation of inflammation and autoimmunity. Front Biosci 2010;15:986-1006.
19. Murphy CA, Langrish CL, Chen Y et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003;198:1951-7.
20. Cornelissen F, Asmawidjaja PS, Mus AM et al. IL-23 dependent and independent stages of experimental arthritis: no clinical effect of therapeutic IL-23p19 inhibition in collagen-induced arthritis. PLoS One 2013;8:e57553.
21. Rasmussen TK, Andersen T, Hvid M et al. Increased interleukin 21 (IL-21) and IL-23 are associated with increased disease activity and with radiographic status in patients with early rheumatoid arthritis. J Rheumatol 2010; 37:2014-20.
22. Tang C, Chen S, Qian H et al. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology 2012;135:112-24.
23. Brentano F, Ospelt C, Stanczyk J et al. Abundant expression of the interleukin (IL)23 subunit p19, but low levels of bioactive IL23 in the rheumatoid synovium: differential expression and Toll-like receptor-(TLR) dependent regulation of the IL23 subunits, p19 and p40, in rheumatoid arthritis. Ann Rheum Dis 2009;68:143-50.
24. Goldberg M, Nadiv O, Luknar-Gabor N et al. Synergism between tumor necrosis factor a and interleukin-17 to induce IL-23 p19 expression in fibroblast-like synoviocytes. Mol Immunol 2009;46:1854-9.
25. Langrish CL, Chen Y, Blumenschein WM et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201:233-40.
26. Ivanov S, Linden A. Interleukin-17 as a drug target in human disease. Trends Pharmacol Dis 2008;30:95-103.
27. Annunziato F, Romagnani S. Heterogeneity of human effector CD4+ T cells. Arthritis Res Ther 2009;11:257.
28. Koenen HJ, Smeets RL, Vink PM et al. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008;112:2340-52.
29. Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 2009; 60:1647-56.
30. Leipe J, Grunke M, Dechant C et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 2010;62: 2876-85.
31. Pene J, Chevalier S, Preisser L et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 2008;180:7423-30.
32. van den Berg W, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 2009;5: 549-553.
33. Gullick NJ, Evans HG, Church LD et al. Linking power Doppler ultrasound to the presence of Th17 cells in the rheumatoid arthritis joint. PLoS One 2010;5:e12516.
34. van Hamburg JP, Asmawidjaja P, Davelaar N et al. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin- 17A production. Arthritis Rheum 2011;63:73-83.
35. Möttönen M, Heikkinen J, Mustonen L et al. CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol 2005; 140:360-7.
36. Herrath J, Müller M, Amoudruz P et al. The inflammatory milieu in the rheumatoid joint reduces regulatory T-cell function. Eur J Immunol 2011;41:2279-90.
37. Annunziato F, Cosmi L, Santarlasci V et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007; 204:1849-61.
38. Hot A, Zrioai S, Toh ML et al. IL-17A- vs. IL-17F-induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in rheumatoid synoviocytes. Ann Rheum Dis 2011;70:341-8.
39. Suurmond J, Dorjée AL, Boon MR et al. Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium. Arthritis Res Ther 2011;13:R150.
40. Metawi SA, Abbas D, Kamal MM et al. Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin Rheumatol 2011;30: 1201-7.
41. Alzabin S, Abraham S, Taher T et al. Incomplete response of inflammatory arthritis to TNFa blockade is associated with Th17 pathway. Ann Rheum Dis 2012;71: 1741-8.
42. Ziolkowska M, Koc A, Luszczykiewicz G et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000;164:2832-8.
43. Hueber AJ, Asquith DL, Miller AM et al. Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 2010; 184:3336-40.
44. Toh ML, Kawashima M, Hot A et al. Role of IL-17 in the Th1 systemic defects in rheumatoid arthritis through selective IL-12Rbeta2. Ann Rheum Dis 2010;69:1562-7.
45. Shahrara S, Pickens SR, Mandelin AM II et al. IL-17- mediated monocyte migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant protein-1 induction. J Immunol 2010;184:4479-87.
46. Koenders MI, Joosten LA, van den Berg WB. Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumor necrosis factor and IL-1 in experimental arthritis. Ann Rheum Dis 2006;65(Suppl 3):29-33.
47. Moran EM, Mullan R, McCormick J et al. Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies. Arthritis Res Ther 2009;11:R113.
48. Toh ML, Gonzales G, Koenders MI et al. Role of interleukin 17 in arthritis chronicity through survival of synoviocytes via regulation of synoviolin expression. PLoS One 2010;5: e13416.
49. Kotake S, Yago T, Kawamoto M et al. Role of osteoclasts and interleukin-17 in the pathogenesis of rheumatoid arthritis: crucial 'human osteoclastology'. J Bone Miner Metab 2012;30:125-35.
50. Adamopoulos IE, Chao CC, Geissler R et al. Interleukin- 17A upregulates receptor activator of NF-kB on osteoclast precursors. Arthritis Res Ther 2010;12:R29.
51. Lubberts E, Joosten LA, Oppers B et al. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 2001;167: 1004-13.
52. Kirkham BW, Lassere MN, Edmonds JP et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 2006;54:1122-31.
53. Pickens SR, Volin MV, Mandelin AM II et al. IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol 2010;184:3233-41.
54. Moran EM, Connolly M, Gao W et al. Interleukin-17A induction of angiogenesis, cell migration, and cytoskeletal rearrangement. Arthritis Rheum 2011;63:3263-73.
55. Marder W, Khalatbari S, Myles JD et al. Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis. Ann Rheum Dis 2011;70:1550-5.
56. Ju JH, Cho ML, Moon YM et al. IL-23 induces receptor activator of NF-kappaB ligand expression on CD4+ T cells and promotes osteoclastogenesis in an autoimmune arthritis model. J Immunol 2008;181:1507-18.
57. Li X, Kim KW, Cho ML et al. IL-23 induces receptor activator of NF-kappaB ligand expression in fibroblast-like synoviocytes via STAT3 and NF-kappaB signal pathways. Immunol Lett 2010;127:100-7.
58. Chen L, Wei XQ, Evans B et al. IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-kappaB (RANK) expression in myeloid precursor cells. Eur J Immunol 2008;38:2845-54.
59. Orozco G, González-Gay MA, Paco L et al. Interleukin 12 (IL12B) and interleukin 12 receptor (IL12RB1) gene polymorphisms in rheumatoid arthritis. Hum Immunol 2005;66: 710-5.
60. Liang YL, Wu H, Shen X et al. Association of STAT4 rs7574865 polymorphism with autoimmune diseases: a meta-analysis. Mol Biol Rep 2012;39:8873-82.
61. Di Meglio P, Di Cesare A, Laggner U et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th-17 effector response in humans. PLoS One 2011;6:e17160.
62. Hazlett J, Stamp LK, Merriman T et al. IL-23R re11209026 polymorphism modulates IL-17A expression in patients with rheumatoid arthritis. Genes Immun 2012;13:282-7.
63. Furst D. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010;39: 327-46.
64. Puel A, Cypowyj S, Bustamante J et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011;332:65-8.
65. Toussirot E. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets 2012;11:159-68.
66. Seavey M, Dobrzanski P. The many faces of Janus kinase. Biochem Pharmacol 2012;83:1136-45.
67. Genovese M, Keystone E, Taylor P et al. 24-week results of a blinded phase 2b dose-ranging study of baricitinib, an oral Janus kinase 1/Janus kinase 2 inhibitor, in combination with traditional disease modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Rheum 2012;64(Suppl):S1049.
68. Vanhoutte F, Mazur M, van der Aa A et al. Selective JAK1 inhibition in the treatment of rheumatoid arthritis: proof of concept with GPLG0634. Arthritis Rheum 2012;64(Suppl): S1051.
69. Fleischmann R, Spender-Green G, Fan F et al. Dose ranging study of VX-509, an oral selective JAK3 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA). Arthritis Rheum 2011;63(Suppl):L3.
70. Hueber W, Patel DD, Dryja T et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010;2: 52ra72.
71. Genovese MC, Durez P, Richards HB et al. One year efficacy and safety results of a phase II trial of secukinumab in patients with rheumatoid arthritis. Arthritis Rheum 2011;63(Suppl):S149-50.
72. Genovese MC, Van den Bosch F, Roberson SA et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebocontrolled, proof-of-concept study. Arthritis Rheum 2010; 62:929-39.
73. Genovese MC, Greenwald MW, Cho CS et al. A phase 2 study of multiple subcutaneous doses of LY2439821, an anti-IL-17 monoclonal antibody, in patients with rheumatoid arthritis in two populations: naïve to biologic therapy or inadequate responders to tumor necrosis factor alpha inhibitors. Arthritis Rheum 2011;63(Suppl):S1017.
74. Papp K, Leonardi C, Menter A et al. Brodalumab, an antiinterleukin- 17-receptor antibody for psoriasis. N Engl J Med 2012;366:1181-98.
75. Pavelka K, Chon Y, Newmark R et al. A randomized, double-blind, placebo-controlled, multiple-dose study to evaluate the safety, tolerability, and efficacy of brodalumab (AMG 827) in subjects with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheum 2012;64(Suppl):S362.
76. Aaltonen KJ, Virkki LM, Malmivaara A et al. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 2012;7:e30275.
77. Alonso-Ruiz A, Pijoan JI, Ansuategui E et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metanalysis of efficacy and safety. BMC Musculoskelet Disord 2008;9:52.
78. Maini RN, Taylor PC, Szechinski J et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54: 2817-29.
79. Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a doubleblind, placebo-controlled, randomised trial. Lancet 2008; 371:987-97.
80. Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicentre, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
81. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-bind, placebocontrolled, dose-ranging trial. Arthritis Rheum 2006;54: 1390-400.